Legal Solutions | USA
Can we help?
Published by the American Bar Association (ABA), ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators is a comprehensive guide examining the intersection between the statutory and regulatory scheme governing approval of generic pharmaceuticals, and U.S. patent law in the context of Paragraph IV ANDA litigation.
Representing a compromise in the pharmaceutical industry in balancing patent exclusivity against market competition, the effect of the Drug Price Competition and Patent Term Restoration Act (commonly known as the Hatch-Waxman Act) on controlling the pharmaceutical market remains unsettled. Amendments to the original act included provisions for an abbreviated process for FDA approval of generic versions of patented pharmaceuticals through the filing of an Abbreviated New Drug Application (ANDA) and the right to initiate patent litigation against an applicant. This law has resulted in ANDA litigation cases and a constant struggle to shape the landscape of the patent and regulatory regime governing FDA-approved patented and generic drugs. The Hatch-Waxman Act with its amendments is a hybrid of two already complex areas of the law – U.S. patent law and FDA regulatory law – which makes patent litigation in this area especially complicated and hotly contested.
In 23 detailed chapters, ANDA Litigation focuses both on the current and developing law as well as the strategies and tactics employed by the litigants. This single-source reference provides both a ready roadmap for novice litigators in the field as well as more detailed material and strategy to assist the more experienced ANDA litigator. The first part details the Hatch-Waxman Act and how it was implemented. Practical tools in these chapters include: an overview of the drug approval process, including required notice and prelitigation considerations, and issues related to the timeline of litigation. Following this, the authors explore even deeper into the actual litigation under the act, with topics covering:
Further chapters are practice-focused, covering issues including:
Finally, the authors discuss remedies, settlement, and antitrust implications, and the book also includes chapters on regulation and litigation of pharmaceuticals outside the U.S.